Software as a Medical Device (SaMD) developer Median Technologies (Euronext Growth Paris:ALMDT) announced on Friday that it has secured up to EUR47.5m in funding to support the regulatory filings and commercialisation of its eyonis Lung Cancer Screening (LCS) software in the United States and European Union.
This includes a potential EUR37.5m loan from the European Investment Bank (EIB) and an equity line of up to EUR10m from IRIS Capital Investment. The EIB loan will be made available in tranches subject to the completion of certain milestones.
The funding will enable Median to complete the US FDA 510(k) and EU CE mark filings for eyonis LCS, expected in Q2 2025, and support its commercial launch in the US market in Q4 2025. Median said that it is currently in active discussions with leading US AI diagnostics companies for potential commercialisation partnerships.
The company has also rescheduled the repayment of its 2020 EIB loan to October 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval